Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Reaffirmed by HC Wainwright : vimarsana.com

HC Wainwright reiterated their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a research report released on Monday morning, Benzinga reports. The brokerage currently has a $9.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Regulus Therapeutics’ Q1 2024 earnings at ($0.19) EPS, Q2 2024 earnings […]

Related Keywords

United States , Leerink Partnrs , Exome Asset Management , Canaccord Genuity Group , Regulus Therapeutics Inc , Wells Fargo Company , Vanguard Group Inc , Hermes Inc , Victory Capital Management Inc , Regulus Therapeutics , Free Report , Genuity Group , Moderate Buy , Get Free Report , Capital Management , Therapeutics Inc , Regulus Therapeutics Daily , Nasdaq Rgls , Rgls , Medical , 75915k10 , Reiterated Rating , Hc Wainwright ,